Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:5a204b352f752248c1c1a38a6195ebc2]
20 patients will be treated with the first planned dose, i.e. 20 µg/mL
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:5a204b352f752248c1c1a38a6195ebc2]
20 patients will be treated with the first planned dose, i.e. 20 µg/mL
Bio2RDF identifier
5a204b352f752248c1c1a38a6195ebc2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:5a204b352f752248c1c1a38a6195ebc2
measure [clinicaltrials_vocabulary:measure]
Symptom Assessment in Dry Eye (SANDE)
time frame [clinicaltrials_vocabulary:time-frame]
Changes from baseline up to day 56±4
description
20 patients will be treated with the first planned dose, i.e. 20 µg/mL
identifier
clinicaltrials_resource:5a204b352f752248c1c1a38a6195ebc2
title
Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4
@en
type
label
Symptom Assessment in Dry Eye ...... 04b352f752248c1c1a38a6195ebc2]
@en